glp-1 and lipedema Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, Fibrosis Half a Year on Compounded

After treatment for 12 months, MDS-UPDRS Part III scores improved slightly by 0.04 points in the lixisenatide group and decreased by 3.04 points in the placebo group

Semaglutide has proven to be a life-changing medication for many people

Effect of metformin treatment on inflammatory markers in type 2 diabetes mellitusA systematic review and meta-analysis

According to Kim Fisher, director of programs at the Institute for Innovation in Food and Health (IIFH) at UC Davis, the scale of metabolic dysfunction in the US is staggering

That evidence provides useful context for understanding why these medications have generated significant patient interest but does not transfer directly to compounded versions, which operate under a different regulatory framework

the Institute for Clinical and Economic Review deemed current GLP-1 prices cost-effective only below USD 7,000 annually, prompting insurers to demand steep rebates